Healthcare
With new and groundbreaking technology constantly challenging the status quo, the healthcare industry is progressing by leaps and bounds. But in an industry built on regulations, strategic partnerships are often the key to successfully developing businesses. Our passionate advisors, backed by sub-sector teams globally, use their deep expertise in M&A, growth equity and ECM, debt advisory and corporate finance services to find your competitive edge, navigate local customs and help you create the most suitable strategy.
Contact advisor
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreNatus welcomes Optima Medical to the Natus family of solutions
The shareholders of Optima Medical Limited have sold the company to Natus Medical Incorporated.
Learn moreUniphar PLC has acquired BModesto Vastgoed B.V.
Irish-listed healthcare group Uniphar PLC has acquired Dutch pharmaceutical services business BModesto Group. The acquisition strengthens Uniphar’s product access offering in Europe.
Learn more
Afsheen Khan
Managing director, Katalyst Diagnostics Ltd.
Read more
Growth and continuity shape Q3 transactions
QUARTERLY M&A ACTIVITY: In Q3 2026, Oaklins clients closed 67 deals across M&A and fundraising, with buyers seeking expertise, customer relationships and new market access.
Learn more
Talk to us
